new_logo.png
GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI
13 juin 2023 17h30 HE | Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...
factMR-logo.png
Peptide-based Metabolic Disorders Therapeutics Market to Surpass US$ 77.9 billion by 2033; As Governments Engage in Supportive Initiatives to Spur Healthcare Sector
01 mars 2023 11h00 HE | FACT.MR
Rockville, March 01, 2023 (GLOBE NEWSWIRE) -- The peptide-based metabolic disorder therapeutics market analysis offered by Fact.MR highlights key growth-shaping factors inducing demand in the...
160223 logo Adocia avec homme qui marche.jpg
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
26 mai 2021 01h30 HE | Adocia SA
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...
泵给药短效多激素组合专利申请将Adoci
泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域
26 mai 2021 01h30 HE | Adocia SA
已申请三项专利系列涵盖新型激素组合:普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权,使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病,例如NASH(非酒精性脂肪性肝炎),2型糖尿病或神经退行性疾病 里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
1ProLynx LOGO.png
ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
12 juin 2017 09h00 HE | ProLynx LLC
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to...